Parallel Advisors LLC Raises Stake in Hologic, Inc. (NASDAQ:HOLX)

Parallel Advisors LLC increased its stake in Hologic, Inc. (NASDAQ:HOLXFree Report) by 11.5% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,828 shares of the medical equipment provider’s stock after buying an additional 189 shares during the quarter. Parallel Advisors LLC’s holdings in Hologic were worth $131,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank purchased a new position in shares of Hologic in the 4th quarter worth about $217,529,000. Nordea Investment Management AB boosted its holdings in shares of Hologic by 4.5% in the 3rd quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock worth $113,077,000 after buying an additional 69,494 shares during the last quarter. Louisiana State Employees Retirement System purchased a new position in shares of Hologic in the 4th quarter worth about $1,057,000. Pathstone Family Office LLC boosted its holdings in shares of Hologic by 96.0% in the 3rd quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock worth $643,000 after buying an additional 4,542 shares during the last quarter. Finally, Ontario Teachers Pension Plan Board boosted its holdings in shares of Hologic by 186.7% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock worth $2,665,000 after buying an additional 25,010 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on HOLX shares. JPMorgan Chase & Co. boosted their price objective on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Evercore ISI boosted their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Finally, Argus boosted their price objective on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $85.60.

View Our Latest Research Report on HOLX

Hologic Trading Up 0.2 %

Shares of HOLX opened at $74.65 on Wednesday. The business’s 50-day moving average price is $75.79 and its 200-day moving average price is $74.04. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $82.45. The stock has a market cap of $17.42 billion, a PE ratio of 38.09, a P/E/G ratio of 2.46 and a beta of 1.00. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLXGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.05. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. Hologic’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.06 earnings per share. On average, equities analysts forecast that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. 1.75% of the stock is owned by company insiders.

Hologic Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

See Also

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.